MarketCap
Facebook
X
Telegram
Altimmune Operating Expenses | ALT
Annual Operating Expenses Altimmune
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 94.5 M | 103 M | 96.4 M | 87.7 M | 101 M | 63 M | 26.3 M | 28.2 M | 26.9 M | 16.5 M | 11.5 M | 20.4 M | 28.8 M | 31.4 M | 36 M | 44.5 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 103 M | 11.5 M | 51 M |
Quarterly Operating Expenses Altimmune
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 22.9 M | 24.2 M | - | 20.9 M | 22.9 M | 21.8 M | - | 24.8 M | 26.8 M | 26.8 M | - | 22.9 M | 18 M | 21.8 M | - | 24.8 M | 20.4 M | 19.5 M | - | 33.4 M | 25 M | 15.7 M | - | 21.3 M | 19.1 M | 9.52 M | - | 11.9 M | 5.18 M | 5.28 M | - | 6.69 M | 7.85 M | 8.69 M | - | 35.5 M | 7.05 M | 4.82 M | - | 5.69 M | 2.35 M | 2.26 M | - | 2.81 M | 3.11 M | 5.91 M | - | 4.96 M | 4.83 M | 6.14 M | - | 6.69 M | 5.78 M | 7.57 M | - | 8.49 M | 7.78 M | 7.74 M | - | 8.28 M | 9.51 M | 10.9 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 35.5 M | 2.26 M | 13.8 M |
Operating Expenses of other stocks in the Biotechnology industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Celsion Corporation
CLSN
|
14.7 M | - | -6.63 % | $ 13.9 M |  USA |
 |
FSD Pharma
HUGE
|
15.3 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
Codexis
CDXS
|
31.5 M | $ 1.42 | 0.33 % | $ 124 M | USA |
 |
Synthetic Biologics
SYN
|
24.1 M | - | 1.32 % | $ 16.2 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
137 M | - | - | $ 2.02 B | USA |
 |
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M |  China |
 |
AgeX Therapeutics
AGE
|
24.2 M | - | -10.17 % | $ 12.2 K | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | USA |
 |
Qilian International Holding Group Limited
QLI
|
2.16 M | - | -6.08 % | $ 184 M | China |
 |
Happiness Biotech Group Limited
HAPP
|
17.1 M | - | 1.35 % | $ 17.8 M | China |
 |
Genfit SA
GNFT
|
78.3 M | - | 2.54 % | $ 160 B |  France |
 |
Cue Biopharma
CUE
|
54 M | $ 27.67 | 2.63 % | $ 2.62 B | USA |
 |
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M |  Germany |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
18.7 M | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
78.4 M | - | 0.74 % | $ 768 M |  Israel |
 |
Abcam plc
ABCM
|
170 M | - | - | $ 4.9 B |  Britain |
 |
Завод ДИОД
DIOD
|
249 M | - | - | - |  Russia |
|
Galera Therapeutics
GRTX
|
70.6 M | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Hepion Pharmaceuticals
HEPA
|
4.16 M | - | -18.79 % | $ 39.3 K | USA |
 |
ARCA biopharma
ABIO
|
122 M | - | 1052.0 % | $ 415 M | USA |
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M | Germany |
 |
Editas Medicine
EDIT
|
201 M | $ 3.08 | 0.33 % | $ 273 M | USA |
 |
Ardelyx
ARDX
|
95.9 M | $ 3.71 | 1.06 % | $ 894 M | USA |
 |
Affimed N.V.
AFMD
|
54 M | - | -34.95 % | $ 21.5 M | Germany |
 |
EyePoint Pharmaceuticals
EYPT
|
275 M | $ 4.57 | 0.21 % | $ 335 K | USA |
 |
Arcutis Biotherapeutics
ARQT
|
305 M | $ 23.66 | 0.04 % | $ 3.01 B | USA |
 |
Assembly Biosciences
ASMB
|
84.4 M | $ 36.13 | 4.38 % | $ 405 M | USA |
 |
Fate Therapeutics
FATE
|
154 M | $ 2.42 | 0.61 % | $ 287 M | USA |
 |
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
106 M | - | -1.58 % | $ 28.1 M | China |
 |
Celyad Oncology SA
CYAD
|
26.2 M | - | - | $ 12.5 M |  Belgium |
 |
Adial Pharmaceuticals
ADIL
|
7.8 M | $ 6.66 | 5.38 % | $ 4.45 M | USA |
 |
Fortress Biotech
FBIO
|
125 M | $ 2.71 | 0.04 % | $ 75.6 M | USA |
 |
Generation Bio Co.
GBIO
|
162 M | - | - | $ 344 M | USA |
 |
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | USA |
 |
Anika Therapeutics
ANIK
|
51.6 M | $ 21.0 | 2.08 % | $ 301 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
9.17 M | - | -4.36 % | $ 27 M | USA |
 |
Gracell Biotechnologies
GRCL
|
214 M | - | - | $ 3.37 B | China |
 |
Axsome Therapeutics
AXSM
|
99.1 M | $ 208.35 | 0.16 % | $ 10.4 B | USA |
 |
GlycoMimetics
GLYC
|
163 M | - | 9357.83 % | $ 1.01 B | USA |
 |
AnaptysBio
ANAB
|
187 M | $ 57.46 | 2.9 % | $ 1.65 B | USA |
 |
Aeterna Zentaris
AEZS
|
13.3 M | - | 5.93 % | $ 314 M | Canada |
 |
AVROBIO
AVRO
|
84 M | - | 1083.1 % | $ 745 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
1.47 B | $ 66.43 | 0.04 % | $ 12.7 B | USA |
 |
BeiGene, Ltd.
BGNE
|
390 M | - | 0.49 % | $ 251 B |  Cayman-islands |